Received for publication 9 April 2004 and accepted in revised form 13 August 2004.J.B.B. is on the advisory board for Amylin Pharmaceuticals. R.R.H. has received honoraria from and served as a consultant for Amylin Pharmaceuticals. *A list of the principle investigators of the Exenatide-113 Clinical Study Group can be found in the APPENDIX . Abbreviations: GLP, glucagon-like peptide; ITT, intent to treat. A table elsewhere in this issue shows conventional and Syste `me International (SI) units and conversion factors for many substances. Â© 2004 by the American Diabetes Association.Emerging Treatments and Technologies ORIGINAL ARTICLE 2628 DIABETES CARE,VOLUME 27, NUMBER 11, N OVEMBER 2004